Idorsia’s Quviviq Needs To Rise And Shine After Slow Launch
US Coverage Negotiations And Celebrity DTC Will Be Significant
Executive Summary
The company’s Quviviq launch has fallen short of early expectations, but Idorsia believes a patient approach will pay off for the blockbuster-tipped insomnia treatment.
You may also be interested in...
Idorsia's Fabry Drug Founders In Phase III
The prospects of lucerastat becoming Idorsia's second drug to be filed with regulators, after the insomnia treatment daridorexant, look slim after a Phase III fail for the Fabry disease therapy.
Beam Therapeutics’ Base-Edited CAR-T Placed On Hold
Beam is the latest allogeneic CAR-T developer to face a regulatory hold-up, but other candidates using its pioneering base-editing technology are now progressing.
On A Roll, AstraZeneca Aims For ‘Industry-Leading’ Growth From 2025
AstraZeneca’s momentum is growing towards ‘industry-leading' revenue growth, but investors are focused on the operating margin, and concerned about when CEO Pascal Soriot will depart.